Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Ophthalmology

Volumn 118, Issue 4, 2011, Pages 609-614

  Elman, Michael J ^a   Bressler, Neil M ^b   Qin, Haijing ^c   Beck, Roy W ^c   Ferris III, Frederick L ^d   Friedman, Scott M ^e   Glassman, Adam R ^c   Scott, Ingrid U ^f   Stockdale, Cynthia R ^c   Sun, Jennifer K ^g  

^a Elman Retina Group   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JAEB CENTER FOR HEALTH RESEARCH   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e Florida Retina Consultants   (United States)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79953299899     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.12.033     Document Type: Article

References (3)

1. Diabetic Retinopathy Clinical Research Network, Elman MJ, AielloLP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
2. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): 12-month data: report 2. Ophthalmology 2010;117:1078-86.
3. U.S. National Institutes of Health ClinicalTrials.gov. Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic macular edema (RESTORE). ClinicalTrials.gov identifer NCT00687804. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00687804? term=nct00687804. Accessed January 5, 2010.